Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03110640
Other study ID # 20170316
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 1, 2016
Est. completion date September 2021

Study information

Verified date November 2019
Source First Affiliated Hospital of Wenzhou Medical University
Contact Kang Yu, M.D.
Phone 55578037
Email yukang62@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm open-label phase I study to determine the effect of CD19- CAR-T Cells infusion followed by allogeneic stem cell transplantation in safety, efficacy and engraftment potential in patients with CD19+ B-lineage leukemia and lymphoma.


Description:

Primary objectives

1. To determine the safety and feasibility of allogeneic stem cell transplantation combined with adoptive transfer of T cells modified to express CD19-specific chimeric antigen receptor (CD19CAR) for treatment of leukemia and lymphoma Secondary objectives

2. To measure the efficacy of the CD19CAR T cell infusion combined with allogeneic stem cell transplantation


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date September 2021
Est. primary completion date June 2020
Accepts healthy volunteers No
Gender All
Age group 5 Years to 70 Years
Eligibility Inclusion Criteria:

- 5 Years to 70 Years, Male and female;

- Expected survival > 12 weeks;

- Performance score 0-2;

- Histologically confirmed as CD19-positive lymphoma/leukemia and who meet one of the following conditions; Patient receive at least 2-4 prior combination chemotherapy regimens (not including single agent monoclonal antibody therapy) and fail to achieve CR; or have disease recurrence; or not eligible for allogeneic stem cell transplantation; or disease responding or stable after most recent therapy but refused further treatment; Disease recurrence after stem cell transplantation; Diagnosis as lymphoma, but refuse conventional treatment such as chemotherapy, radiation, stem cell transplantation and monoclonal antibody therapy

- Creatinine < 2.5 mg/dl;

- ALT/AST < 3x normal;

- Bilirubin < 2.0 mg/dl;

- Adequate venous access for apheresis, and no other contraindications for leukapheresis;

- Take contraceptive measures before recruit to this trial;

- Written voluntary informed consent is given.

Exclusion Criteria:

- Patients with symptoms of central nervous system

- Accompanied by other malignant tumor

- Active hepatitis B or C, HIV infection

- Any other diseases could affect the outcome of this trial

- Suffering severe cardiovascular or respiratory disease

- Poorly controlled hypertension

- A history of mental illness and poorly controlled

- Taking immunosuppressive agents within 1 week due to organ transplantation or other disease which need long-lasting administration

- Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment

- Reaching a steady dose if receiving anticoagulant therapy before assignment

- Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion

- Pregnant or lactating women

- Subject suffering disease affects the understanding of informed consent or comply with study protocol.

Study Design


Related Conditions & MeSH terms

  • Adult Acute Lymphoblastic Leukemia in Remission
  • B-cell Adult Acute Lymphoblastic Leukemia
  • B-cell Chronic Lymphocytic Leukemia
  • Hematopoietic/Lymphoid Cancer
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Refractory Chronic Lymphocytic Leukemia

Intervention

Biological:
anti-CD19 CAR-T
Ex vivo-expanded autologous T cells modified to express CD19 CAR
Drug:
Fludarabine
Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
Cyclophosphamide
Patients were given cyclophosphamide 500mg/m2/day on day -4.

Locations

Country Name City State
China The First Affilicated Hospital of Wenzhou Medical University Wenzhou Zhejiang

Sponsors (3)

Lead Sponsor Collaborator
First Affiliated Hospital of Wenzhou Medical University Hrain Biotechnology Co., Ltd., Second Affiliated Hospital of Nanchang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety - incidence of adverse events defined as dose-limited toxicity incidence of adverse events defined as dose-limited toxicity 180 days
Secondary Overall complete remission rate Overall complete remission rate 1 year
Secondary Duration of remission Duration of remission 1 year
See also
  Status Clinical Trial Phase
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03045328 - Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Phase 2
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Active, not recruiting NCT01369849 - Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 1/Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Terminated NCT00387426 - Sunitinib in Treating Patients With Idiopathic Myelofibrosis Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00006226 - Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Phase 2
Completed NCT00005803 - Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Phase 1/Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Active, not recruiting NCT04230304 - Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Phase 2
Recruiting NCT04007029 - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04892277 - CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Active, not recruiting NCT04578600 - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Phase 1
Completed NCT02240719 - Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer Phase 1
Terminated NCT01408043 - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma N/A
Completed NCT01441882 - Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Phase 2